CY1110278T1 - Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια - Google Patents

Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια

Info

Publication number
CY1110278T1
CY1110278T1 CY20101100159T CY101100159T CY1110278T1 CY 1110278 T1 CY1110278 T1 CY 1110278T1 CY 20101100159 T CY20101100159 T CY 20101100159T CY 101100159 T CY101100159 T CY 101100159T CY 1110278 T1 CY1110278 T1 CY 1110278T1
Authority
CY
Cyprus
Prior art keywords
obesity
activity
expression
concerns
cure
Prior art date
Application number
CY20101100159T
Other languages
English (en)
Inventor
Sophie Tartare-Deckert
Obberchen Emmanuel Van
Original Assignee
Merck Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante filed Critical Merck Sante
Publication of CY1110278T1 publication Critical patent/CY1110278T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση έχει ως αντικείμενο μία μέθοδο διαλογής παραγόντων ικανών να αντιμετωπίζουν, κατά προληπτικό ή θεραπευτικό τρόπο, την παχυσαρκία ή μία από τις διαταραχές που συνδέονται με την παχυσαρκία δια ρυθμίσεως της εκφράσεως της πρωτείνης SPARC ή της δράσεως της. Αφορά επίσης μία μέθοδο διαγνώσεως της παχυσαρκίας ή μίας από τις διαταραχές που συνδέονται με την παχυσαρκία παρακολουθώντας την έκφραση της πρωτεΐνης SPARC ή της δράσεως της. Αφορά μία σύνθεση περιλαμβάνουσα τουλάχιστον έναν παράγοντα ρυθμίζοντα την έκφραση ή τη δράση της πρωτεΐνης SPARC. Αφορά επίσης τη χρήση οποιουδήποτε παράγοντα ο οποίος ρυθμίζει την έκφραση ή τη δράση της πρωτεΐνης SPARC για την παρασκευή μίας φαρμακευτικής συνθέσεως προοριζόμενης για την αγωγή, κατά προληπτικό ή θεραπευτικό τρόπο, της παχυσαρκίας ή μίας από τις διαταραχές που συνδέονται με την παχυσαρκία.
CY20101100159T 2000-11-10 2010-02-18 Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια CY1110278T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0014487A FR2816633B1 (fr) 2000-11-10 2000-11-10 Methode de criblage d'agents susceptibles de traiter l'obesite
EP01993389A EP1332229B1 (fr) 2000-11-10 2001-11-08 Methode de criblage d'agents susceptibles de traiter l'obesite

Publications (1)

Publication Number Publication Date
CY1110278T1 true CY1110278T1 (el) 2015-01-14

Family

ID=8856316

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100159T CY1110278T1 (el) 2000-11-10 2010-02-18 Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια

Country Status (14)

Country Link
US (1) US7651844B2 (el)
EP (1) EP1332229B1 (el)
JP (1) JP4044842B2 (el)
AT (1) ATE453726T1 (el)
AU (1) AU2304202A (el)
CA (1) CA2428492A1 (el)
CY (1) CY1110278T1 (el)
DE (1) DE60140953D1 (el)
DK (1) DK1332229T3 (el)
ES (1) ES2336649T3 (el)
FR (1) FR2816633B1 (el)
NZ (1) NZ525608A (el)
PT (1) PT1332229E (el)
WO (1) WO2002038807A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4814774B2 (ja) 2006-12-06 2011-11-16 花王株式会社 肥満調節剤の評価方法
US20110138888A1 (en) * 2008-07-21 2011-06-16 Amany Elshorbagy Treatment of obesity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054485A (en) * 1996-08-20 2000-04-25 Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US6239326B1 (en) * 1996-11-07 2001-05-29 The Wistar Institute Of Anatomy And Biology Sparc-deficient transgenic mice
EP0950097A2 (en) * 1996-12-27 1999-10-20 Instituto de Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy

Also Published As

Publication number Publication date
ES2336649T3 (es) 2010-04-15
NZ525608A (en) 2005-11-25
EP1332229A1 (fr) 2003-08-06
US20040049799A1 (en) 2004-03-11
FR2816633B1 (fr) 2003-02-07
DK1332229T3 (da) 2010-05-03
CA2428492A1 (fr) 2002-05-16
DE60140953D1 (de) 2010-02-11
ATE453726T1 (de) 2010-01-15
PT1332229E (pt) 2010-03-10
AU2304202A (en) 2002-05-21
WO2002038807A1 (fr) 2002-05-16
EP1332229B1 (fr) 2009-12-30
JP4044842B2 (ja) 2008-02-06
US7651844B2 (en) 2010-01-26
FR2816633A1 (fr) 2002-05-17
JP2004517308A (ja) 2004-06-10

Similar Documents

Publication Publication Date Title
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
EP1474687A4 (en) MARK AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
HK1069767A1 (en) Methods for inhibiting ocular processes
MY140767A (en) Compounds, methods and compositions
DE69737592D1 (de) Mittel gegen juckreiz
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
EP0895781A3 (en) Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
NO20010446L (no) Substituert anilidforbindelser og metoder
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE399557T1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
TR199700956T1 (xx) Indazolkarboksamidler.
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
EP1254260A4 (en) METHODS FOR DIAGNOSING AND TREATING A HEART DISEASE
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE259379T1 (de) Fluoresceinisothiocyanat-(fitc)-sinistrin, seine herstellung und verwendung
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
WO2002062205A3 (en) Methods for diagnosing and treating heart disease